Advertisement
U.S. markets closed
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • Dow 30

    37,983.24
    -475.84 (-1.24%)
     
  • Nasdaq

    16,175.09
    -267.10 (-1.62%)
     
  • Russell 2000

    2,003.17
    -39.43 (-1.93%)
     
  • Crude Oil

    85.45
    +0.43 (+0.51%)
     
  • Gold

    2,360.20
    -12.50 (-0.53%)
     
  • Silver

    27.97
    -0.28 (-0.99%)
     
  • EUR/USD

    1.0646
    -0.0085 (-0.79%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • GBP/USD

    1.2451
    -0.0104 (-0.83%)
     
  • USD/JPY

    153.2400
    +0.0370 (+0.02%)
     
  • Bitcoin USD

    67,246.18
    -2,862.02 (-4.08%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    39,523.55
    +80.92 (+0.21%)
     

Anavex Soars on Positive Alzheimer’s Results

Anavex Life Sciences Corp. (AVXL) was one of the stocks helping to prop up the market in Monday’s session. The company reported a positive dose-response relationship has been observed in a pre-planned interim analysis of data from the ongoing Phase 2a trial of Anavex 2-73 for treatment of mild to moderate Alzheimer’s disease.

Among 32 patients treated with doses of Anavex 2-73 ranging from 3 mg to 50 mg a day, the Mini Mental State Examination (MMSE) score data showed a positive slope with confidence intervals not including the zero-value, consistent with a dose dependent improvement in MMSE scores over five weeks.

ALSO READ: 12 Things Not to Do If You Win the $1.3 Billion Lottery

Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented:

While we remain cautious about interpreting the results of an interim analysis, evidence of ANAVEX 2-73’s positive dose response at 5 weeks on the MMSE is a welcome signal. Evidence of a dose-response relationship is one of the factors taken into account by regulatory agencies when ultimately considering medications for approval.

Christopher U. Missling, PhD, president and CEO of Anavex, added:

Our team is encouraged by these findings and we look forward to advancing ANAVEX 2-73 into a larger Phase 2/3 study for Alzheimer’s as well as initiating a double-blinded, randomized, placebo-controlled Phase 2 trial for ANAVEX 2-73 in an additional indication associated with cognitive impairment.

ALSO READ: Best and Worst Car Brands in America


Previously the company announced positive data for its Anavex 3-71, which is also involved in the treatment of Alzheimer’s. Despite the positive data that this company has been releasing surrounding its Alzheimer’s study, the stock has dropped nearly 30% in the past month and 17% year to date.

Shares of Anavex were last seen trading up 10.4% at $5.08, with a consensus analyst price target of $10.16 and a 52-week trading range of $3.16 to $14.84.

Related Articles

Advertisement